Biologically targeted treatment of non-small-cell lung cancer: Focus on epidermal growth factor receptor

Clinical Lung Cancer

Volumn 5, Issue SUPPL. 1, 2003, Pages

  Natale, Ronald B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gefitinib; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; LIGAND; MONOCLONAL ANTIBODY; PACLITAXEL; PELITINIB; PLACEBO; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW DISEASE; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG APPROVAL; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL DISEASE; GENE THERAPY; HEART DISEASE; HUMAN; INHIBITION KINETICS; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; RASH; SOLID TUMOR; SYMPTOM; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

EID: 0142029049     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.s.010     Document Type: Article

References (67)

1. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-S8.
2. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410:83-86.
3. Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8:151-159.
4. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8:11-31.
5. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001; 28 (suppl 16):67-79.
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
7. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(suppl):32s-40s.
8. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60 (suppl 1):25-32.
9. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53:2379-2385.
10. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522.
11. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241-249.
12. Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002; 16:19-24.
13. Dancey JE, Schoenfeldt M. Clinical trials referral resource: epidermal growth factor receptor inhibitors in clinical trials. Oncology (Huntingt) 2001; 15:748-758.
14. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
15. Kusaba H, Tamura T, Nakagawa K, et al. A phase I intermittent dose-escalation trial of ZD1839 (Iressa™) in Japanese patients with solid malignant tumors. Clin Cancer Res 2000; 6 (suppl):4543s (Abstract #381).
16. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19:177a (Abstract #686).
17. Bonomi P, Perez-Soler R, Chachoua A, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Clin Cancer Res 2000; 6 (suppl):4544s (Abstract #386).
18. Laurie SA, Miller VA, Johnson D, et al. Pilot trial of ZD1839 (Iressa™), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000; 29 (suppl 1):71 (Abstract #230).
19. Bonner JA, Ezekiel MP, Robert F, et al. Continued response following treatment with IMC-C225, an EGFr MoAb combined with RT in advanced head and neck malignancies. Proc Am Soc Clin Oncol 2000; 19:4a (Abstract #5F).
20. Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1862).
21. Siu LL, Hidalgo M, Nemunaitis J, et al. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774: a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 1999; 18:388a (Abstract #1498).
22. Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:326a (Abstract #1301).
23. Gonzalez-Larriba JL, Giaccone G, van Oosterom AT, et al. ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial. Proc Am Soc Clin Oncol 2002; 21:95a (Abstract #376).
24. Forouzesh B, Hidalgo M, Takimoto C, et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 2002; 21:21a (Abstract #81).
25. Forero L, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002; 21:25b (Abstract #1908).
26. Ratain MJ, George CM, Janisch L, et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21:76b (Abstract #2115).
27. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20:130a (Abstract #518).
28. Hong WK, Arquette M, Nabell L, et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001; 20:224a (Abstract #895).
29. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10:505-510.
30. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-124.
31. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.
32. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176.
33. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
34. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
35. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
36. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
37. Williams KJ, Telfer BA, Stratford IJ, et al. Combination of ZD1839 ("Iressa"), an EGFR-TKI, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model. Proc Am Assoc Cancer Res 2001; 42:715 (Abstract #3840).
38. She Y, Lee F, Haimovitz-Friedman A, et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') enhances radiation sensitivity of human tumor xenografts in nude mice. Proc Am Assoc Cancer Res 2002; 43:786 (Abstract #3894).
39. Ciardiello F, Damiano V, Bianco R, et al. Inhibition of EGFR-tyrosine kinase by ZD1839 ('Iressa') leads to antiproliferative and antiangiogenic effects in human GEO colon cancer xenografts, in combination with paclitaxel. Proc Am Assoc Cancer Res 2001; 42:854 (Abstract #4580).
40. Solomon B, Hagekyriakou J, Trivett M, et al. Potentiation of the antitumor effect of ionizing radiation by ZD1839 ("Iressa" in vitro and in vivo in A431 cells. Proc Am Assoc Cancer Res 2002; 43:1002 (Abstract #4966).
41. Bianco R, Bianco C, Caputo R, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) by ZD1839 ('Iressa') potentiates the antitumor effects of ionizing radiation. Proc Am Assoc Cancer Res 2002; 43:1003 (Abstract #4972).
42. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
43. Goss GD, Hirte H, Lorimer I, et al. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamic (PD), and biological activity study of ZD1839: NCIC CTG Ind. 122. Proc Am Soc Clin Oncol 2001; 20:85a (Abstract #335).
44. Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours. Proc Am Soc Clin Oncol 2001; 20:324a (Abstract #1292).
45. Baselga J, LoRusso P, Herbst R, et al. A pharmacokinetic/pharmacodynamic trial of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with five selected tumor types (a phase I/II trial of continuous once-daily treatment). Presented at: American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer; November 16-19, 1999; Washington, DC.
46. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid rumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
47. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
48. Kris M, Ranson M, Ferry D, et al. Phase I study of oral ZD1839 ('Iressa'), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. Presented at: American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer; November 16-19, 1999; Washington, DC.
49. Ferry D, Hammond L, Ranson M, et al. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki) shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 2000; 19:3a (Abstract #5E).
50. Kris M, Ranson M, Ferry D, et al. Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. Clin Cancer Res 1999; 5 (suppl):3749s-3750s (Abstract #99).
51. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1166).
52. Natale RB, Skarin AT, Maddox AM, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1167).
53. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with previously treated advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21:298a (Abstract #1188).
54. Douillard JY, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21:299a (Abstract #1195).
55. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2002; 21:2237-2246.
56. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002; 13 (suppl 5):2-3 (Abstract #4O).
57. Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa") in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13 (suppl 5):127-128 (Abstract #468O).
58. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-207.
59. Bianco R, Yakes FM, Mills GB, et al. EGF receptor-overexpressing tumor cells that lack PTEN/MMAC1 and RB are resistant to small molecule EGFR kinase inhibitors. Proc Am Assoc Cancer Res 2001; 42:851 (Abstract #4567).
60. Iressa® (gefitinib) tablets prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2003
61. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137-139.
62. Reckzeh B, Merte H, Pflüger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14:1071-1076.
63. Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002; 25:509-512.
64. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001; 13:242-248.
65. Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36:2329-2334.
66. Collard HR, King TE Jr. Demystifying idiopathic interstitial pneumonia. Arch Intern Med 2003; 163:17-29.
67. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304.